ºÚÁÏÍø

ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
ºÚÁÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ºÚÁÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 3330

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Recommended Journals
Share This Page

Modeling and docking studies of DKK-1, a novel receptor in HCC pathway

6th World Congress on Biotechnology

Sandhya Hora Wadhawan and Deepshikha Pande Katare

Amity University, India

Posters-Accepted Abstracts: J Biotechnol Biomater

DOI:

Abstract
Hepatocellular carcinoma (HCC) is the fifth malignant tumor and the second leading cause of cancer related mortality worldwide. The major reason for high prevalence of HCC is poor diagnosis at early stage. Prognostic biomarkers of HCC are still not absolutely ready for introduction into clinical trials because they have restricted sensitivity and specificity. Serum Dickkopf-1 (DKK1) plays an important role in HCC progression which is a secretory protein in Wnt/�²-catenin signaling pathway. The sensitivity and specificity of DKK1 are good to diagnose HCC. The 3-D structure of DKK1 was modeled and used for docking against various compounds extracted from marine organisms. These compounds have anti-cancerous activities and some of them are already in clinical trials. The compound with best binding energies will be taken forward to design inhibitors of DKK1.
Biography

Sandhya Hora Wadhawan is a PhD Scholar in Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University and has completed her Master’s in Biotechnology from Chaudhary Charan Singh University, Meerut. She has worked as a Research Assistant in SRMS-Institute of Medical Sciences, Bareilly for two years and published 3 papers in reputed national journals.

Email: sandhya.hora@gmail.com

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top